Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis: One protein, two healing properties.

× No keyword cloud information.

7 in total

1. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors: Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal: Nat Immunol Date: 2005-10-02 Impact factor: 25.606

2. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.

Authors: Stefano Pluchino; Angelo Quattrini; Elena Brambilla; Angela Gritti; Giuliana Salani; Giorgia Dina; Rossella Galli; Ubaldo Del Carro; Stefano Amadio; Alessandra Bergami; Roberto Furlan; Giancarlo Comi; Angelo L Vescovi; Gianvito Martino
Journal: Nature Date: 2003-04-17 Impact factor: 49.962

3. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Authors: Joanne L Jones; Jane M Anderson; Chia-Ling Phuah; Edward J Fox; Krzysztof Selmaj; David Margolin; Stephen L Lake; Jeffrey Palmer; Sara J Thompson; Alastair Wilkins; Daniel J Webber; D Alastair Compston; Alasdair J Coles
Journal: Brain Date: 2010-07-21 Impact factor: 13.501

4. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6.

Authors: Wenda Gao; Lorraine Thompson; Qiang Zhou; Prabhakar Putheti; Tarek M Fahmy; Terry B Strom; Su M Metcalfe
Journal: Cell Cycle Date: 2009-05-04 Impact factor: 4.534

5. CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis.

Authors: Helena Slaets; Jerome J A Hendriks; Chris Van den Haute; Frea Coun; Veerle Baekelandt; Piet Stinissen; Niels Hellings
Journal: Mol Ther Date: 2010-01-12 Impact factor: 11.454

Review 6. The unsolved enigmas of leukemia inhibitory factor.

Authors: Donald Metcalf
Journal: Stem Cells Date: 2003 Impact factor: 6.277

7. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

Authors: Jason Park; Wenda Gao; Roy Whiston; Terry B Strom; Su Metcalfe; Tarek M Fahmy
Journal: Mol Pharm Date: 2010-12-08 Impact factor: 4.939

7 in total

3 in total

1. Leukemia Inhibitory Factor Inhibits Plasmacytoid Dendritic Cell Function and Development.

Authors: Renata Sesti-Costa; Luisa Cervantes-Barragan; Melissa K Swiecki; José Luís Fachi; Marina Cella; Susan Gilfillan; João Santana Silva; Marco Colonna
Journal: J Immunol Date: 2020-03-13 Impact factor: 5.422

Review 2. Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.

Authors: Su M Metcalfe; Sean Bickerton; Tarek Fahmy
Journal: Curr Pharm Des Date: 2017 Impact factor: 3.116

Review 3. Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF.

Authors: Su M Metcalfe; Terry B Strom; Anna Williams; Tarek M Fahmy
Journal: Nanobiomedicine (Rij) Date: 2015-01-01

3 in total